SCS AUA 2025
SCS AUA 2025
SCS AUA 2025: Oncological and Surgical Outcomes of Endoscopic Therapy Compared to Surgical Resection of Upper Tract Urothelial Carcinoma Stratified by Tumor Grade: Analysis of National Cancer Database
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on urothelial carcinoma, featuring a presentation from Dr. Renil Titus discussing oncological and surgical outcomes of endoscopic therapy compared to surgical resection of upper tract urothelial carcinoma stratified by tumor grade. Treatment with endoscopic or surgical resection of upper tract urothelial carcinoma is risk-stratified based on histological, radiographic, and clinical findings. Alternative approaches due to chronic kidney disease or for solitary kidneys where radical nephroureterectomy is unfavourable include endoscopic ablation or segmental ureterectomy. However, oncological outcomes of endoscopic treatment versus surgical resection (radical nephroureterectomy or segmental ureterectomy) are not well defined. Dr. Titus and colleagues queried the American College of Surgeons - National Cancer Database (ACS-NCDB) to compare the overall survival and surgical outcomes of endoscopic treatment to surgical resection for localized upper tract urothelial carcinoma stratified by grade – high and low.
SCS AUA 2025: Is There a Role for an Intraoperative Steep Trendelenburg Break During Robot-Assisted Laparoscopic Radical Prostatectomies? Results from an Academic Training Program
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on prostate cancer, featuring a presentation from Dr. Arnold Palacios discussing the role for an intraoperative steep Trendelenburg break during robot-assisted laparoscopic radical prostatectomies (RALP). Notably, steep Trendelenburg positioning may increase the risk of position-related complications in patients undergoing a RALP. An intraoperative break in steep Trendelenburg could potentially decrease the risk of these complications. In this study, Dr. Palacios and colleagues assessed the perioperative outcomes observed in patients undergoing a RALP at their institution and evaluated the impact a steep Trendelenburg break had on positioning-related complications.
SCS AUA 2025: Long-Term Outcomes of Adjuvant UGN-101 in a Real-World Cohort
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on urothelial cancer, featuring a presentation from Dr. Patrick Burnam discussing long-term outcomes of adjuvant UGN-101 in a real-world cohort. Kidney-sparing surgery in upper tract urothelial carcinoma (UTUC) is employed in patients with low-risk disease or imperative indications with the goal of preserving kidney function without compromising oncologic outcomes.
SCS AUA 2025: Efficacy and Safety of Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Regimen in Metastatic RCC
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Dr. Emily Elliott discussing the efficacy and safety of cytoreductive nephrectomy following immune checkpoint inhibitor combination regimen in metastatic renal cell carcinoma (RCC). Cytoreductive nephrectomy had been the standard of care in metastatic RCC for nearly 20 years prior to systemic therapy. However, the randomized CARMENA trial demonstrated sunitinib alone was noninferior to cytoreductive nephrectomy followed by sunitinib in metastatic RCC patients with intermediate to poor risk disease.1
SCS AUA 2025: Underreporting of CIS in Patients with High-Grade Papillary NMIBC
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. R. Jonathan Henderson discussing underreporting of CIS in patients with high-grade papillary non muscle invasive bladder cancer. Patients with high-grade Ta/T1 non muscle invasive bladder cancer often have concomitant CIS. However, the rate is variable, and pathologists may not examine every bladder biopsy once a high-grade papillary lesion is identified.
SCS AUA 2025: Contemporary Outcomes for Radical Nephrectomy with Inferior Vena Cava Thrombectomy in the Era of Pre-Operative Immunotherapy
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Ryan Packham discussing contemporary outcomes for radical nephrectomy with inferior vena cava thrombectomy in the era of pre-operative immunotherapy. Renal cell carcinoma (RCC) often presents with venous tumor thrombus, requiring complex IVC thrombectomy, which carries significant morbidity and mortality.
SCS AUA 2025: Pre-Clinic Educational Information’s Effect on Anxiety in Patients with Renal Masses
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Dr. Jared Starkey discussing pre-clinic educational information’s effect on anxiety in patients with renal masses. The psychological burden associated with a new diagnosis of a renal mass is considerable, manifesting as heightened anxiety levels in patients.
SCS AUA 2025: Novel Therapeutic Regimens in Previously Untreated Metastatic Urothelial Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. David Hinojosa-Gonzalez discussing novel therapeutic regimens in previously untreated metastatic urothelial carcinoma. Metastatic urothelial carcinoma has historically had few effective therapeutic options.
SCS AUA 2025: Oncologic Outcomes of Kidney-Sparing Surgery with or Without Adjuvant UGN-101 in Upper Tract Urothelial Carcinoma: A Single Institution Series
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on urothelial cancer, featuring a presentation from Dr. Mark Doss discussing oncologic outcomes of kidney-sparing surgery with or without adjuvant UGN-101 in upper tract urothelial carcinoma.
SCS AUA 2025: Low Serum Testosterone Level and Biopsy Grade Group Progression Among Men with Prostate Cancer on Active Surveillance
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on prostate cancer, featuring a presentation from Dr. Tarek Lawen discussing low serum testosterone level and biopsy grade group progression among men with prostate cancer on active surveillance. Hypogonadism, defined as low serum testosterone, is associated with increased rates of adverse pathology at radical prostatectomy.
SCS AUA 2025: Penelope: Tissue Penetration of Gemcitabine Phosphate Metabolites Following TAR-200 Administration Versus Standard Intravesical Instillation in Minipigs
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. Yair Lotan discussing an assessment of tissue penetration of gemcitabine phosphate metabolites following TAR-200 administration versus standard intravesical instillation in minipigs. Gemcitabine has been used for many years as an intravesical instillation to treat non muscle invasive bladder cancer; however, its short half life (<3 hours) limits tissue exposure. TAR-200 is a novel intravesical targeted releasing system designed to provide local continuous/sustained release of gemcitabine within the bladder, with potentially deep-tissue penetration. The preclinical Penelope study evaluated the penetration of gemcitabine (dFdC) and its active metabolites, diphosphate and triphosphate of dFdC (dFdCDP, dFdCTP), in bladder tissues up to 96 hours after TAR-200 administration or intravesical instillation.
SCS AUA 2025: Trials in Progress: BOND-003 Cohort P: A Multi-Institutional, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-Unresponsive NMIBC
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a trials in progress presentation from Colin Dinney, MD, discussing updates to the BOND-003 Cohort P trial. Patients presenting with high risk BCG-unresponsive non muscle invasive bladder cancer have limited treatment options.
SCS AUA 2025: Trial in Progress: PIVOT-006 – a Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate Risk NMIBC
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a trials in progress presentation from Dr. Robert Svatek discussing the PIVOT-006 trial. AUA guidelines recommend adjuvant intravesical therapy or surveillance for patients diagnosed with intermediate risk non muscle invasive bladder cancer. Despite this, up to 60% of patients will recur, and there is a general lack of level-1 evidence in the management of intermediate risk non muscle invasive bladder cancer disease. As a result, there is both a knowledge gap and an unmet medical need for improved therapies for intermediate risk non muscle invasive bladder cancer patients.
SCS AUA 2025: Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk NMIBC
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a trials in progress presentation from Colin Dinney, MD, discussing updates to the CORE-008 trial. Treatment for patients with high-risk non-muscle invasive bladder cancer consists of TURBT followed by intravesical BCG, yet high recurrence rates and the ongoing BCG shortage highlight the need for effective, well-tolerated, and readily available treatment options.
SCS AUA 2025: Streamlined, Patient-Centric Design of the Cretostimogene Grenadenorepvec Expanded Access Program in Patients with NMIBC Unresponsive to BCG
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a trials in progress presentation from Dr. Yair Lotan discussing a streamlined, patient-centric design of the cretostimogene grenadenorepvec expanded access program in patients with non-muscle invasive bladder cancer unresponsive to BCG.
SCS AUA 2025: Incidental Prostate Lesions on FDG PET/CT and Prostate Cancer Risk: A Single-Center Retrospective Study
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on prostate cancer, featuring a presentation from Dr. Hunter Kraus discussing the impact of incidental prostate lesions on FDG PET/CT and prostate cancer risk. Overall, 1-3% of patients without known prostate cancer who undergo FDG PET/CT will be found to have an incidental, FDG-avid lesion in the prostate, of which 10-20% of patients are subsequently found to have prostate cancer. The indication for prostate biopsy is typically based on digital rectal exam, PSA levels, family history, and shared-decision making. However, there are limited studies evaluating the utility of prostate MRI in patients with incidental FDG-positive lesions in the prostate. At the 2025 South Central AUA annual meeting, Dr. Kraus and colleagues presented an institutional experience regarding the work up of incidental prostate lesions on FDG PET/CT and the role of prostate MRI in the decision-making process.
SCS AUA 2025: Cytoreductive Nephrectomy after Immune Checkpoint Inhibitor Therapy in Metastatic RCC
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Dr. Emily Leding discussing cytoreductive nephrectomy after immune checkpoint inhibitor therapy in metastatic renal cell carcinoma (RCC). The role of cytoreductive nephrectomy in the management of metastatic RCC has evolved with immune checkpoint inhibitors as first-line therapy. While emerging evidence suggests post-immune checkpoint inhibitor cytoreductive nephrectomy may offer survival benefit for select patients, the safety, perioperative risks, and surgical outcomes remain unclear. Immune checkpoint inhibitors are known to cause immune-related adverse events that could impact surgical outcomes, including delayed wound healing, increased risk of thromboembolic events, and higher perioperative complication rates. Understanding these risks is critical for optimizing patient selection and perioperative care strategies. This study aimed to evaluate the safety and perioperative outcomes of post-immune checkpoint inhibitor cytoreductive nephrectomy, with a focus on complication rates, recovery parameters, and early oncologic outcomes in patients with metastatic RCC.
SCS AUA 2025: Preliminary Results from LEGEND: A Phase 2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Genetic Medicine for High-Risk NMIBC
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. Yair Lotan discussing preliminary results from LEGEND, a phase 2 study of detalimogene voraplasmid, a novel, investigational, non-viral genetic medicine for high-risk non-muscle invasive bladder cancer. Bladder sparing therapies for high-risk non-muscle invasive bladder cancer address an important unmet need:
SCS AUA 2025: Patient Decision Making and Treatment Preferences for Localized Renal Masses: A Prospective Study
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Merrick Huang discussing patient decision making and treatment preferences for localized renal masses. The incidence of renal masses is rising, with over 80,000 new kidney and renal pelvis cancer cases estimated in 2024, and up to 70% detected incidentally.
SCS AUA 2025: Improving the Identification of Predictive Risk Factors to Refine the Indication of Adjuvant Therapy in Intermediate Localized and Locally Advanced RCC Patients
- Details
(UroToday.com) The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Dr. Horst Emanuel Lagos Beitz discussing the identification of predictive risk factors to refine the indication of adjuvant therapy in intermediate localized and locally advanced renal cell carcinoma (RCC) patients. Pembrolizumab is indicated as adjuvant therapy for RCC patients with adverse clinical and histopathologic characteristics based on results from the KEYNOTE 426 trial.1,2 However, outcomes vary within this group, and identifying patients with lower recurrence risk could reduce unnecessary treatment and adverse effects. This is particularly relevant in resource-limited settings where access to immunotherapy is financially restrictive. The goal of the current study was to identify predictive factors associated with recurrence to optimize patient selection for adjuvant therapy while maintaining oncological outcomes in intermediate- and high-risk localized and locally advanced RCC patients.